EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Targeting ER lipid raft-associated 1 reveals a coordinated cholesterol-dependent vulnerability in hepatocellular carcinoma

Yiming Zhang, Yushan Hou, Xinxin Wang, Kaikun Xu, Pei Jiang, Siqi Wang, Huimin Kang, Hu Zhang, Jingzhuo Jin, Xiaofen Huang, Zifeng Liu, Songpeng Yang und 5 weitere

Clinical and Molecular Hepatology · 01.04.2026 · 32 (2) · 866-883

DOI: 10.3350/cmh.2025.1157 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.04.2026. Verfasst von Yiming Zhang und 16 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Research Unit of Proteomics Driven Cancer Precision Medic…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Cholesterol, Membrane Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Dysregulated cholesterol metabolism is a hallmark of hepatocellular carcinoma (HCC) that drives tumor initiation and progression. However, clinical targeting of cholesterol metabolism has yielded limited benefits due to stringent feedback in tumor cells. Identifying a central mediator capable of restoring cholesterol homeostasis within the cell’s intrinsically fine-tuned regulatory framework is urgently needed.

Methods

We integrated a proteomic dataset from patients with cholesterol-dysregulated HCC into a global cholesterol metabolic regulatory network to identify potential therapeutic targets for disrupted cholesterol homeostasis. The prognostic significance of the candidate targets was further validated in an independent cohort through immunohistochemistry. Functional and mechanistic studies were conducted in vitro using HCC cell lines and in vivo using mouse models. The pharmacological efficacy of the candidate agent was evaluated in both subcutaneous and orthotopic HCC mouse models.

Results

ER lipid raft-associated 1 (ERLIN1), a pivotal regulator of cholesterol metabolism reprogramming, was identified as an independent favorable prognostic indicator in HCC. ERLIN1 constrains HCC progression both in vitro and in vivo by stabilizing the INSIG1–SCAP–SREBP2 axis and maintaining the metabolic balance of intracellular cholesterol. Under hypoxia, impaired factor-inhibiting hypoxia-1-dependent hydroxylation of ASB11 at asparagine residues 90 and 92 enhances ASB11-mediated ERLIN1 degradation. Pharmacological targeting of this axis using zoledronic acid (ZoA) attenuated HCC progression by weakening the ASB11–ERLIN1 interaction and restoring cholesterol homeostasis.

Conclusions

ERLIN1 represents a druggable metabolic vulnerability in cholesterol-dysregulated HCC. Targeting the ASB11–ERLIN1 axis with the clinically approved ZoA reestablishes cholesterol homeostasis and offers a promising therapeutic strategy to overcome the current limitations of cholesterol-targeted HCC therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsCholesterolMembrane ProteinsHumansAnimalsMiceCell Line, TumorIntracellular Signaling Peptides and ProteinsSterol Regulatory Element Binding Protein 2PrognosisProteomics

Stichwörter der Autor:innen

Cholesterol metabolism reprogrammingERLIN1Factor inhibiting hypoxia inducible factorHypoxia

Substanzen

CholesterolMembrane ProteinsSREBP cleavage-activating proteinIntracellular Signaling Peptides and ProteinsSterol Regulatory Element Binding Protein 2INSIG1 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Research Unit of Proteomics Driven Cancer Precision Medicine (Chinese Academy of Medical Sciences), Beijing, China.
  • Department of Pathology, Beijing You'an Hospital, Capital Medical University, Beijing, China.
  • School of Basic Medical Sciences, University of South China, Hengyang, Hunan, China.
  • College of Life Sciences, Hebei University, Baoding, China.

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
  • Guangdong Provincial Hospital of Chinese Medicine

Zitieren

APA

Zhang, Y., Hou, Y., Wang, X., Xu, K., Jiang, P., Wang, S., Kang, H., Zhang, H., Jin, J., Huang, X., Liu, Z., Yang, S., Liu, J., Zhang, L., He, F., Tian, C., & Sun, A. (2026). Targeting ER lipid raft-associated 1 reveals a coordinated cholesterol-dependent vulnerability in hepatocellular carcinoma. Clinical and Molecular Hepatology, 32(2), 866-883. https://doi.org/10.3350/cmh.2025.1157

Vancouver

Zhang Y, Hou Y, Wang X, Xu K, Jiang P, Wang S, et al. Targeting ER lipid raft-associated 1 reveals a coordinated cholesterol-dependent vulnerability in hepatocellular carcinoma. Clinical and Molecular Hepatology. 2026;32(2):866-883. doi:10.3350/cmh.2025.1157

BibTeX
@article{Zhang2026,
  author = {Zhang, Yiming and Hou, Yushan and Wang, Xinxin and Xu, Kaikun and Jiang, Pei and Wang, Siqi and Kang, Huimin and Zhang, Hu and Jin, Jingzhuo and Huang, Xiaofen and Liu, Zifeng and Yang, Songpeng and Liu, Jiaqi and Zhang, Lingqiang and He, Fuchu and Tian, Chunyan and Sun, Aihua},
  title = {Targeting ER lipid raft-associated 1 reveals a coordinated cholesterol-dependent vulnerability in hepatocellular carcinoma},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  volume = {32},
  number = {2},
  pages = {866--883},
  doi = {10.3350/cmh.2025.1157}
}
Kostenlos starten →